Poor prognostic factors independently impact remission and treatment escalation in rheumatoid arthritis regardless of disease activity: A nationwide prospective cohort study
Main finding · Point Boolean-based remission in 5-year (moderately-to-highly active patients at baseline)Result — go to the resultHR for attaining point Boolean-based remission 0.55 95% CI 0.38–0.79Authors' conclusion
Achieving remission was particularly challenging for group H, and more patients in groups M and H initiated b/tsDMARDS during the 5-year observation period.
Study context
- Population
- Patients with rheumatoid arthritis (RA) in the Korean KORONA database; Poor prognostic factors (PPFs): functional limitation, extra-articular disease, seropositivity, bone erosions
- Participants
- 5,076 patients
- Exposure
- RA patients by number of poor prognostic factors: ≥3 and 2 vs 0-1
- Group Ln = 1,788reference
- Group Mn = 2,027
- Group Hn = 1,261
- Outcome
- Achieving remission and initiating b/tsDMARDs
- Follow-up
- 5-year
Methodological detailsnationwide, Cox proportional hazard regression adjusted for confounders
- Nationwide
- Cox proportional hazard regression adjusted for confounders
Main finding
As reported in the abstract
Point Boolean-based remission in 5-year (moderately-to-highly active patients at baseline)
HR for attaining point Boolean-based remission
0.55
95% CI 0.38–0.79
Group Hvs Group L
HR for attaining point Boolean-based remission 0.55 (95% CI 0.38–0.79)
Observational data: associations, not effects.
Further findings
| Outcome | Estimate | |
|---|---|---|
| Sustained Boolean-based remission in 5-year (moderately-to-highly active patients at baseline)Group Hvs Group LGroup H significantly less likely to attain remission | HR for attaining sustained Boolean-based remission 0.45 (95% CI 0.21–0.99) | |
| Escalation to b/tsDMARDs (b/tsDMARD-naïve patients at baseline)Group Mvs Group L | HR for escalation to b/tsDMARDs 1.47 (95% CI 1.10–1.96) | |
| Escalation to b/tsDMARDs (b/tsDMARD-naïve patients at baseline)Group Hvs Group L | HR for escalation to b/tsDMARDs 1.69 (95% CI 1.22–2.32) | |
| 0.20.5125Ratio (log scale) |
Original publication
Poor prognostic factors independently impact remission and treatment escalation in rheumatoid arthritis regardless of disease activity: A nationwide prospective cohort study. Joint Bone Spine. Published 24 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →